Rhythm Pharma Appoints Murray Stewart Chief Medical Officer

Murray Stewart has been appointed chief medical officer of Rhythm Pharmaceuticals (NASDAQ: [[ticker:RYTM]]). Stewart joins Boston-based Rhythm from Novelion Therapeutics (NASDAQ: [[ticker:NVLN]]), where he was head of R&D. His experience also includes 18 years at GlaxoSmithKline (NYSE: [[ticker:GSK]]), where he held several roles, including chief medical officer. Last year, Rhythm raised $120 million in an IPO to finance continued work on setmelanotide, a late-stage drug candidate developed to treat genetic obesity disorders.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.